

Ivana Sestak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/956628/publications.pdf>

Version: 2024-02-01

86
papers

7,961
citations

125106

35
h-index

81351

76
g-index

87
all docs

87
docs citations

87
times ranked

8619
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy. <i>European Journal of Cancer</i> , 2022, 164, 52-61.	1.3	0
2	Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 115-123.	1.1	12
3	Calibration of CTS5 in Women With Early Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 338-339.	0.8	3
4	Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 126-135.	0.8	69
5	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. <i>British Journal of Cancer</i> , 2021, 124, 1373-1378.	2.9	3
6	Abstract PS18-10: Intratumoural heterogeneity in PgR expression: Molecular and prognostic significance. , 2021, , .		0
7	Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®. <i>Npj Breast Cancer</i> , 2021, 7, 15.	2.3	11
8	The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 215-223.	1.1	10
9	A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk. <i>Cancers</i> , 2021, 13, 3303.	1.7	8
10	Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. <i>Clinical Cancer Research</i> , 2020, 26, 623-631.	3.2	10
11	Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. <i>Lancet</i> , The, 2020, 395, 117-122.	6.3	128
12	Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial. <i>Breast</i> , 2020, 54, 216-221.	0.9	12
13	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4682-4687.	3.2	22
14	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 377-386.	1.1	61
15	Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. <i>Bone</i> , 2019, 124, 83-88.	1.4	9
16	Risk stratification in early breast cancer in premenopausal and postmenopausal women: integrating genomic assays with clinicopathological features. <i>Current Opinion in Oncology</i> , 2019, 31, 29-34.	1.1	14
17	Breast Cancer Index and risk stratification in luminal subtypes: A trans-ATAC study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 534-534.	0.8	0
18	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 545.	3.4	246

#	ARTICLE	IF	CITATIONS
19	Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II. <i>Annals of Oncology</i> , 2018, 29, 504-509.	0.6	21
20	Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 166-175.	3.0	122
21	Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. <i>Journal of Clinical Oncology</i> , 2018, 36, 1941-1948.	0.8	116
22	Diffuse reflectance spectroscopy for field scale assessment of winter wheat yield. <i>Environmental Earth Sciences</i> , 2018, 77, 1.	1.3	5
23	Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 103.	2.2	7
24	Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 553-553.	0.8	2
25	Overweight and breast cancer risk in the International Breast Cancer Intervention studies I and II. <i>Journal of Clinical Oncology</i> , 2018, 36, 1560-1560.	0.8	0
26	Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study. <i>Journal of Clinical Oncology</i> , 2018, 36, 529-529.	0.8	1
27	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 743-750.	0.8	58
28	HER2 status predicts for upfront AI benefit: AÂTRANS-AIOG meta-analysis of 12,129 patients fromÂATAC, BIG 1-98 and TEAM with centrally determined HER2. <i>European Journal of Cancer</i> , 2017, 79, 129-138.	1.3	21
29	Radioactivity of Selected Agricultural Soils in Croatia: Effects of Soil Properties, Soil Management, and Geological Parameters. <i>Water, Air, and Soil Pollution</i> , 2017, 228, 1.	1.1	7
30	Identifying Biomarkers to Select Patients with Early Breast Cancer Suitable for Extended Adjuvant Endocrine Therapy. <i>Breast Care</i> , 2017, 12, 146-151.	0.8	8
31	Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). <i>Journal of Clinical Oncology</i> , 2017, 35, 2666-2673.	0.8	40
32	IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer. <i>Breast</i> , 2016, 29, 147-152.	0.9	18
33	Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 425-432.	1.2	1
34	Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5043-5048.	3.2	18
35	Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. <i>International Journal of Cancer</i> , 2016, 139, 2127-2134.	2.3	30
36	Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 591-596.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw149.	3.0	165
38	Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 71-78.	1.1	11
39	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 866-873.	6.3	149
40	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 139-143.	0.8	30
41	Improved use of clinical variables for prognosis of distant recurrence in patients with ER+ breast cancer treated with 5 years endocrine therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, 566-566.	0.8	4
42	Abstract 1788: Benefit of low-dose tamoxifen in a large, single-institution cohort of high-risk ER-positive DCIS. , 2016, , .		0
43	Impact of preventive therapy on the risk of breast cancer among women with benign breast disease. <i>Breast</i> , 2015, 24, S51-S55.	0.9	31
44	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2763-2770.	3.2	36
45	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. <i>Lancet Oncology</i> , The, 2015, 16, 67-75.	5.1	349
46	Markers for the identification of late breast cancer recurrence. <i>Breast Cancer Research</i> , 2015, 17, 10.	2.2	60
47	Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 309-318.	1.1	37
48	Update on breast cancer risk prediction and prevention. <i>Current Opinion in Obstetrics and Gynecology</i> , 2015, 27, 92-97.	0.9	27
49	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. <i>BMC Medical Genomics</i> , 2015, 8, 54.	0.7	352
50	Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. <i>Journal of Clinical Oncology</i> , 2015, 33, 916-922.	0.8	189
51	Abstract PD4-1: Timing, severity and risk factors for arthralgia in the IBIS-II trial: A retrospective and exploratory analysis. , 2015, , .		0
52	Abstract S3-07: 16 year long-term follow-up of the IBIS-I breast cancer prevention trial. , 2015, , .		0
53	Abstract P3-06-01: Nuclear β -catenin negativity predicts for late relapse in ER+, tamoxifen-treated breast cancer. , 2015, , .		0
54	Abstract P4-11-19: Integration of breast cancer index (BCI) with clinicopathological factors for prediction of distant recurrence in ER+ breast cancer. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
55	Correlation of Breast Cancer Index HOXB13/IL17BR (H/I), ER, PR and HER2 and prediction of relative endocrine benefit from tamoxifen and anastrozole in HR+ breast cancer: A TransATAC study.. Journal of Clinical Oncology, 2015, 33, 526-526.	0.8	1
56	Preventative therapies for healthy women at high risk of breast cancer. Cancer Management and Research, 2014, 6, 423.	0.9	21
57	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncology, The, 2014, 15, 1460-1468.	5.1	56
58	Altered Microenvironment Promotes Progression of Preinvasive Breast Cancer: Myoepithelial Expression of α 2 β 1 Integrin in DCIS Identifies High-risk Patients and Predicts Recurrence. Clinical Cancer Research, 2014, 20, 344-357.	3.2	77
59	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, The, 2014, 383, 1041-1048.	6.3	504
60	Soil Carbon Variability in Some Hungarian and Croatian Soils. , 2014, , 419-426.		2
61	Use of a SNP panel to refine risk estimates in women at high risk of breast cancer: Results from two randomized tamoxifen prevention trials.. Journal of Clinical Oncology, 2014, 32, 1519-1519.	0.8	1
62	Clinical impact of differential risk stratification by breast cancer index (BCI) versus recurrence score (RS) in HR+ early-stage breast cancer: A TransATAC study.. Journal of Clinical Oncology, 2014, 32, 532-532.	0.8	0
63	Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncology, The, 2013, 14, 1067-1076.	5.1	332
64	Comparison of PAM50 Risk of Recurrence Score With OncoDX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. Journal of Clinical Oncology, 2013, 31, 2783-2790.	0.8	557
65	Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Research and Treatment, 2013, 140, 253-262.	1.1	13
66	The effect of behavioural risk factors on osteoporosis in Irish women. Irish Journal of Medical Science, 2013, 182, 97-105.	0.8	5
67	Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet, The, 2013, 381, 1827-1834.	6.3	391
68	Factors Predicting Late Recurrence for Estrogen Receptor-Positive Breast Cancer. Journal of the National Cancer Institute, 2013, 105, 1504-1511.	3.0	200
69	CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients. Journal of the National Cancer Institute, 2012, 104, 452-460.	3.0	247
70	Sulphur cycling between terrestrial agroecosystem and atmosphere. Arhiv Za Higijenu Rada I Toksikologiju, 2012, 63, 301-310.	0.4	3
71	ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Research, 2012, 14, R46.	2.2	46
72	Preventive Therapy for Breast Cancer. Current Oncology Reports, 2012, 14, 568-573.	1.8	5

#	ARTICLE	IF	CITATIONS
73	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2012, 38, 318-328.	3.4	77
74	Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. <i>British Journal of Cancer</i> , 2012, 107, 230-233.	2.9	18
75	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 727-734.	1.1	47
76	Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. <i>Lancet Oncology, The</i> , 2011, 12, 21-29.	5.1	476
77	10-year analysis of the ATAC trial: wrong conclusion? Authors' reply. <i>Lancet Oncology, The</i> , 2011, 12, 217.	5.1	2
78	Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4266-4272.	0.8	61
79	Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3411-3415.	0.8	271
80	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2010, 11, 1135-1141.	5.1	1,017
81	Aromatase Inhibitor-Induced Carpal Tunnel Syndrome: Results From the ATAC Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4961-4965.	0.8	75
82	Breast cancer chemoprevention. <i>Oncology Reviews</i> , 2008, 2, 223-228.	0.8	6
83	Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. <i>Lancet Oncology, The</i> , 2008, 9, 866-872.	5.1	186
84	Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. <i>Lancet Oncology, The</i> , 2008, 9, 1143-1148.	5.1	171
85	Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 272-282.	3.0	510
86	Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms. <i>Journal of Clinical Oncology</i> , 2006, 24, 3991-3996.	0.8	42